Free Trial

SELLAS Life Sciences Group (SLS) Competitors

SELLAS Life Sciences Group logo
$2.18 +0.01 (+0.23%)
As of 11:08 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SLS vs. DNA, AVXL, TNGX, ABUS, PVLA, URGN, GYRE, PRME, IOVA, and RZLT

Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Ginkgo Bioworks (DNA), Anavex Life Sciences (AVXL), Tango Therapeutics (TNGX), Arbutus Biopharma (ABUS), Palvella Therapeutics (PVLA), Urogen Pharma (URGN), Gyre Therapeutics (GYRE), Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

SELLAS Life Sciences Group vs. Its Competitors

SELLAS Life Sciences Group (NASDAQ:SLS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 9 mentions for SELLAS Life Sciences Group and 3 mentions for Ginkgo Bioworks. SELLAS Life Sciences Group's average media sentiment score of 0.79 beat Ginkgo Bioworks' score of 0.15 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Ginkgo Bioworks
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 1.4% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Ginkgo Bioworks. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences Group$1M273.30-$30.88M-$0.32-6.83
Ginkgo Bioworks$227.04M4.12-$547.03M-$5.86-2.70

SELLAS Life Sciences Group currently has a consensus target price of $7.00, indicating a potential upside of 220.37%. Ginkgo Bioworks has a consensus target price of $9.00, indicating a potential downside of 43.04%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, equities analysts plainly believe SELLAS Life Sciences Group is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

SELLAS Life Sciences Group has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -136.56%. Ginkgo Bioworks' return on equity of -43.25% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -132.51% -92.79%
Ginkgo Bioworks -136.56%-43.25%-22.29%

Summary

SELLAS Life Sciences Group beats Ginkgo Bioworks on 9 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

MetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$272.05M$3.42B$6.16B$10.59B
Dividend YieldN/A2.30%5.73%4.78%
P/E Ratio-6.8023.1085.6727.43
Price / Sales273.30450.35584.77183.24
Price / CashN/A46.1137.3961.86
Price / Book16.8110.6812.516.79
Net Income-$30.88M-$52.47M$3.32B$276.90M
7 Day Performance15.30%1.08%707.60%0.29%
1 Month Performance30.84%16.86%935.16%7.59%
1 Year Performance74.80%16.25%2,403.40%39.41%

SELLAS Life Sciences Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLS
SELLAS Life Sciences Group
1.8293 of 5 stars
$2.19
+0.2%
$7.00
+220.4%
+81.7%$272.05M$1M-6.8010Options Volume
Gap Up
DNA
Ginkgo Bioworks
1.1877 of 5 stars
$13.20
-2.4%
$9.00
-31.8%
+102.5%$800.38M$230.82M-2.25640
AVXL
Anavex Life Sciences
3.7245 of 5 stars
$8.62
-7.0%
$44.00
+410.4%
+67.5%$796.24MN/A-15.1240
TNGX
Tango Therapeutics
1.2484 of 5 stars
$8.47
+18.6%
$10.50
+24.0%
+37.8%$794.40M$42.07M-6.3790
ABUS
Arbutus Biopharma
1.1244 of 5 stars
$4.28
+4.1%
$5.00
+16.8%
+8.8%$787.88M$6.17M-14.7690Negative News
PVLA
Palvella Therapeutics
2.0354 of 5 stars
$76.22
+9.0%
$75.50
-0.9%
N/A$773.07M$42.81M-6.30N/A
URGN
Urogen Pharma
3.979 of 5 stars
$16.76
+0.5%
$32.00
+90.9%
+41.0%$771.69M$90.40M-5.05200
GYRE
Gyre Therapeutics
1.7316 of 5 stars
$8.39
+5.4%
$17.00
+102.6%
-34.6%$766.65M$105.76M839.8440News Coverage
PRME
Prime Medicine
0.6395 of 5 stars
$5.65
-0.5%
N/AN/A$764.38M$2.98M-3.62N/A
IOVA
Iovance Biotherapeutics
4.4926 of 5 stars
$2.14
+1.9%
$11.90
+456.1%
-76.6%$759.89M$164.07M-1.74500
RZLT
Rezolute
2.4431 of 5 stars
$8.07
-2.4%
$14.50
+79.7%
+86.7%$751.15MN/A-8.3240

Related Companies and Tools


This page (NASDAQ:SLS) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners